By Andrea Park
A tissue sample was taken from Lacks without her consent in 1951 and was subsequently used to develop the first polio vaccine, HPV vaccines, gene-mapping techniques and more.
read more
By Heather Landi
Digital health startups focused on women's health care pulled in $1.3 billion in funding so far in 2021—nearly doubling all of 2020's funding with four months still left to go. The new wave of women's digital health funding is pushing beyond historical norms of pregnancy and fertility support to more comprehensive offerings, from primary care to chronic disease management and menopause, accord to a report from Rock Health.
read more
By Kevin Dunleavy
How will the emergence of Merck's antiviral molnupiravir affect the demand for vaccines and other COVID treatments? Analysts from the ODDO BHF financial services group say molnupiravir will have little impact on vaccines. Bernstein also weighs in on the effect on antivirals.
read more
By Conor Hale
After inking a $795 million deal this summer to absorb a maker of fully automated diagnostics aimed at infectious diseases, Hologic is hitting the road with its newfound prize and launching the Novodiag system for labs in Europe.
read more
By Angus Liu
Many companies have shifted their way of working amid COVID-19. Adjusting to how work is done these days, GlaxoSmithKline is downsizing its office footprint in the U.S. by moving to new locations.
read more
By Robert King
Employer health plans cannot deny benefits to customers who don't get vaccinated for COVID-19 but they can offer premium discounts for getting vaccinated, new CMS guidance says.
read more
By Eric Sagonowsky
Revance Therapeutics has traveled a long road to a potential FDA approval for its Botox competitor, including COVID delays that pushed back plant inspections. Now, it faces a new obstacle: a patent lawsuit from drug giant AbbVie.
read more
By Kyle LaHucik
Contract research organization Inotiv is making another deal, this time doling out total consideration of $15 million for drug discovery company Plato BioPharma. The Colorado-based in vivo pharmacology research company adds to Inotiv's August buy of Gateway Pharmacology Laboratories.
read more